Fibrogen reports fourth quarter and full year 2023 financial results

•   topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2q 2024 •   additional data from phase 1 monotherapy study of fg-3246 in metastatic castration-resistant prostate cancer (mcrpc) expected in 1q 2024 •   fibrogen regains rights to roxadustat from astrazeneca in the united states and other astrazeneca territories, except china and south korea •   fy 2023 total net revenue of $147.8 million, an increase of 5% year over year •   robust roxadustat volume growth of 41% in china in fy 2023 compared to fy 2022 •   successful execution of cost reduction plan; $248.1 million in cash provides cash runway into 2026 san francisco, feb. 26, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company's recent developments. “we are extremely excited about the company's prospects in 2024,” said thane wettig, chief executive officer, fibrogen.
FGEN Ratings Summary
FGEN Quant Ranking